Evidence map›Paper›PMID 39777254›Full record

ArticleBrain communications2025

A data-driven model of disability progression in progressive multiple sclerosis.

Sara Garbarino, Carmen Tur, Marco Lorenzi, Matteo Pardini, Michele Piana, Antonio Uccelli, Douglas L Arnold, Bruce A C Cree, Maria Pia Sormani, Francesca Bovis

Abstract read
In one paragraph

Article in Brain communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Sara GarbarinoLife Science Computational laboratory, IRCCS Ospedale Policlinico San Martino, 16132 Genoa, Italy.ORCID https://orcid.org/0000-0002-3583-3630
Carmen TurMultiple Sclerosis Centre of Catalonia (Cemcat), Department of Neurology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, 08035 Barcelona, Spain.ORCID https://orcid.org/0000-0003-1849-3184
Marco LorenziUniversitè Côte d'Azur, Inria, Epione Research Project, 06902 Sophia Antipolis, France.
Matteo PardiniDepartment of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, Università di Genova, 16132 Genoa, Italy.
Michele PianaLife Science Computational laboratory, IRCCS Ospedale Policlinico San Martino, 16132 Genoa, Italy.
Antonio UccelliDepartment of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, Università di Genova, 16132 Genoa, Italy.ORCID https://orcid.org/0000-0002-2008-6038
Douglas L ArnoldMcGill University, H3A0G4 Montréal, Canada.
Bruce A C CreeUCSF Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, 94143 San Francisco, USA.
Maria Pia SormaniIRCCS Ospedale Policlinico San Martino, 16132 Genoa, Italy.
Francesca BovisDepartment of Health Sciences (DISSAL), Università di Genova, 16132 Genoa, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study applies the Gaussian process progression model, a Bayesian data-driven disease progression model, to analyse the evolution of primary progressive multiple sclerosis. Utilizing data from 1521 primary progressive multiple sclerosis participants collected within the International Progressive Multiple Sclerosis Alliance Project, the analysis includes 18 581 longitudinal time-points (average follow-up time: 28.2 months) of disability assessments including the expanded disability status scale, symbol digit modalities, timed 25-foot-walk, 9-hole-peg test and of MRI metrics such as T1 and T2 lesion volume and normalized brain volume. From these data, Gaussian process progression model infers a data-driven description of the progression common to all individuals, alongside scores measuring the individual progression rates relative to the population, spanning ∼50 years of disease duration. Along this timeline, Gaussian process progression model identifies an initial steep worsening of the expanded disability status scale that stabilizes after ∼30 years of disease duration, suggesting its diminished utility in monitoring disease progression beyond this time. Conversely, it underscores the slower evolution of normalized brain volume across the disease duration. The individual progression rates estimated by Gaussian process progression model can be used to identify three distinct sub-groups within the primary progressive multiple sclerosis population: a normative group (76% of the population) and two 'outlier' sub-groups displaying either accelerated (13% of the population) or decelerated (11%) progression compared to the normative one. Notably, fast progressors exhibit older age at symptom onset (38.5 versus 35.0,

Indexed as

Bayesian learningdata-driven disease progression modellingmultimodal dataPPMS sub-groupsprimary progressive multiple sclerosis

Identifiers

PMID39777254
PMCPMC11704797

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.